EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics

Michael J Marino, P Jeffrey Conn, Jeffrey P Conn

Current Drug Target -CNS & Neurological Disorders · 2002

DOI: 10.2174/1568007023339319 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Drug Target -CNS & Neurological Disorders, 2002. Verfasst von Michael J Marino und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Merck Research Laboratories, Merck & Co. Inc., 770 Sumneytown Pike, West Point, PA 19486-0004, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The basal ganglia are implicated in a number of disorders including neurodegenerative motor diseases such as Huntington's and Parkinson's disease, as well as psychiatric disorders such as schizophrenia and obsessive compulsive disorder. In recent years, a great deal of effort has been focused on determining the basal ganglia circuitry that underlies normal behavior, as well as many of these syndromes. This has led to a detailed understanding of both the normal and pathophysiological flow of information through the basal ganglia, and has provided the opportunity to begin developing novel pharmacological methods of intervention by targeting neuromodulatory receptors with in the basal ganglia circuit. One group of receptors that holds much promise for several basal ganglia disorders is the metabotropic glutamate receptors. Data from behavioral, neurochemical, neuroanatomical and electrophysiological studies has begun to reveal the functional roles that the metabotropic glutamate receptors play in modulating the basal ganglia circuit, and suggests that compounds selectively targeting these receptors may provide novel therapies for a variety of disorders including Parkinson's disease, addiction, and epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsBasal GangliaDrug Delivery SystemsHumansMental DisordersReceptors, Metabotropic Glutamate

Substanzen

Receptors, Metabotropic Glutamate

Autor:innen und Institutionen

  • Department of Neuroscience, Merck Research Laboratories, Merck & Co. Inc., 770 Sumneytown Pike, West Point, PA 19486-0004, USA.

Zitieren

APA

Marino, M. J., Conn, P. J., & Conn, J. P. (2002). Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics. Current Drug Target -CNS & Neurological Disorders. https://doi.org/10.2174/1568007023339319

Vancouver

Marino MJ, Conn PJ, Conn JP. Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics. Current Drug Target -CNS & Neurological Disorders. 2002. doi:10.2174/1568007023339319

BibTeX
@article{Marino2002,
  author = {Marino, Michael J and Conn, P Jeffrey and Conn, Jeffrey P},
  title = {Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics},
  journal = {Current Drug Target -CNS & Neurological Disorders},
  year = {2002},
  doi = {10.2174/1568007023339319}
}
Kostenlos starten →